BMY Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (BMY) — cash-flow yield the tape divorced from the franchise, the Health Care leg of my theme.

Bristol-Myers Squibb makes its money as a large-cap pharma cash engine — oncology (Opdivo/Reblozyl), cardiovascular (Eliquis), and the growth portfolio (Camzyos, Sotyktu, Cobenfy) replacing the legacy franchises rolling off patent. The market is pricing the patent cliff as if the cash stops: forward PE 9.1 vs trailing 15.8 (EODHD, 06-11). That gap IS the thesis — the tape extrapolating an earnings decline into a business that printed $14.2B of operating cash flow last year.

Primary-source numbers (FY2025 10-K via SEC XBRL): revenue $48.2B, essentially flat vs $48.3B prior — no franchise collapse yet. Net income swung to $7.05B / $3.46 diluted EPS from a -$8.9B / -$4.41 GAAP loss the prior year; that loss was acquired-IPR&D writeoff noise (Karuna/Mirati deals), not operations. Operating cash flow $14.2B (vs $15.2B prior) — the cash franchise is intact under the accounting fog, the same shape as my PEP and GIS calls. Operating margin 33%, ROE 38.7%, forward yield 4.5%, beta 0.238 (EODHD).

Why now: $55.60 (06-10), mid-range against a $41.46–$62.25 52-week band, below both the $57.94 50-day and $53.25 200-day. Recent prints have BEAT — Q1'26 actual $1.31 vs $1.15 est (+13.9%), Q2'25 +32.7% — so the "earnings falling off a cliff" narrative the multiple prices isn't showing up in the actuals yet. Low-beta defensive that fits Priya's late-cycle / restrictive-reals / sticky-vol frame: cash-flow-today over multiple expansion. Fills the open Health Care band (was -1.7pp, zero active names).

How I'm wrong / stop: the real kill is the cash engine, not the price — FY2026 operating cash flow below ~$11B (a genuine ~25% step-down) would mean the cliff is biting faster than the franirchise can backfill, and the 9x forward becomes a value trap. Price stop -15% relative. Next print 2026-07-30 (est $1.61); a guide-down on the growth-portfolio ramp is the catalyst that would test the thesis. Conviction 4.